Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Household spending rises 5.9% in 2017 — PSA

2018-07-19 bworldonline
HOUSEHOLD SPENDING increased 5.9% in 2017 though 13 of 17 regions posted slower growth rates, according to data released by the Philippine Statistics Authority (PSA).
SYBJF RZLLY RCB SECB

1
FS Bancorp, Inc. and Anchor Bancorp Agree to Merge in a Transaction Valued at Approximately $77 Million

2018-07-18 globenewswire
MOUNTLAKE TERRACE, Wash. and LACEY, Wash., July 17, 2018 (GLOBE NEWSWIRE) -- FS Bancorp, Inc. ("FS Bancorp ") (NASDAQ:FSBW) and Anchor Bancorp ("Anchor") (NASDAQ:ANCB) announced today the signing of a definitive merger agreement and plan of merger (the “Agreement”) whereby FS Bancorp will acquire Anchor in a stock and cash transaction valued at approximately $77 million. As of March 31, 2018, on a pro forma consolidated basis, the combined company would have approximately $1.
ABCW FSWB SYBJF ANCB WAFD WAFDW FSBW SECB

0
PSE index up on thin trade

2018-07-17 business.inquirer.net
The local stock barometer managed to slightly firm up on Tuesday but at an alarmingly low value turnout.
ABZPF SMIVY PSKXF SVTMF ABZPY SYBJF PHSXY SM PSE SECB AP

0
Investors turn attention to earnings reports

2018-07-17 bworldonline
THE MAIN INDEX eked out last-minute gains on Tuesday after moving within a tight range as investors await the release of corporate earnings results in the coming weeks.
PSKXF BDOUY AYAAY UVRBY SECB BDOUF BDO MWP SYBJF URC PHSXY PSE MWIDE ALI UVRBF AYAAF

0
PH stocks gain more ground

2018-07-13 business.inquirer.net
The local stock barometer firmed up for the fourth straight session yesterday, flirting with the 7,400 mark in intra-day trade in line with mostly upbeat regional markets.
PSKXF SYBJF PHSXY PSE SECB

0
Vista Land signs P7.7-B corporate note facility

2018-07-13 bworldonline
VISTA Land & Lifescapes, Inc. (VLL) has secured corporate note facilities totaling P7.7 billion to fund its capital expenditures this year.
PSKXF CHIB SYBJF PHSXY PSE SECB CKGOY

0
VLL signs corporate notes facility worth P7.7 billion

2018-07-13 bworldonline
Vista Land & Lifescapes, Inc. (VLL) has secured corporate note facilities totaling P7.7 billion to fund its capital expenditures this year.
CHIB VLL SYBJF SECB CKGOY

0
PSEi keeps pace with optimistic Asian neighbors, marking 3rd day of rally

2018-07-12 business.inquirer.net
The local stock barometer gained for the third straight session yesterday, tracking mostly firmer regional markets.
ABZPF PSKXF ABZPY SYBJF PHSXY PSE SECB AP

0
Yields on gov’t debt mixed

2018-07-08 bworldonline
YIELDS saw mixed movements last week as investors priced in the escalating trade war between the US and China and after domestic inflation reached a fresh five-year high.
SYBJF SECB

0
Factory output growth eases but remains robust in May

2018-07-05 bworldonline
THE COUNTRY’S factory production continued to expand by double-digit pace for the fifth straight month in May, though at a slower clip than in the preceding month, the Philippine Statistics Authority (PSA) reported on Thursday.
SYBJF RZLLY RCB SECB

0
PSEi rallies to 7,300 level, but market still seen technically weak

2018-07-04 business.inquirer.net
The local stock barometer rallied to the 7,300 level yesterday on the back of some foreign inflows amid expectations that the market may have found the bottom.
BDOUF BDO SMIVY PSKXF SVTMF BDOUY SYBJF PHSXY SM PSE SECB

0
PSEi closes up 0.55%; next barrier seen at 7,440-7,500

2018-07-03 business.inquirer.net
The local stock barometer yesterday crept higher for the third straight session as domestic investors selectively picked up large-cap stocks dumped by foreign players.
GLO PSKXF GTMEY SYBJF PHSXY PSE GTMEF GLOPP GLOPA SECB

4
June factory growth buoys Q2 reading

2018-07-02 bworldonline
IMPROVEMENT in manufacturing activity eased in June from the preceding month as increases in output and new orders ebbed, according to the latest survey IHS Markit conducted for Nikkei, Inc. that nevertheless showed last month’s “solid” growth pushing the second quarter’s average Purchasing Managers’ Index reading higher than that of January-March.
SYBJF SECB

8
Food, oil to stoke June inflation

2018-07-01 bworldonline
INFLATION likely clocked in faster in June on the back of rising food and oil prices coupled with a weaker peso, economists said in a BusinessWorld poll, with some noting that another rate hike may still be on the table for the central bank to temper prices.
SYBJF RZLLY RCB SECB

4
FS Bancorp, Inc. /1st Security Bank of Washington added to membership of Russell 3000® Index

2018-06-29 globenewswire
MOUNTLAKE TERRACE, Wash., June 29, 2018 (GLOBE NEWSWIRE) -- FS Bancorp, Inc. (NASDAQ:FSBW), the parent company of 1st Security Bank of Washington, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opened on June 25, as part of the 2018 Russell indexes reconstitution.
FSWB SYBJF FSBW SECB

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...